Target Volume Determination 2015

CTV L4-L3: 1-3 N+: INDICATIONS

Randomized trials are PENDING:

RTOG 9915 (SWOG)



 EORTC (SUPREMO – Selective Use of Postoperative Radiotherapy After Mastectomy): In this trial, apart from randomize 1-3 N(+) patients, pT2 pN0 with grade 3 and/or vasculo-lymphatic invasion are also randomized.

NCI CTG



French study



EBCTG META-ANALYSIS: POSITIVE RESULTS OF SURVIVAL 1-3 N+

↓ 7.9%

↓ 11.5%